trial

Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia

NCTId NCT00621634
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by Université de Montréal
Primary completion 2010-02-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-02
Primary completion
2010-02-01
Eligibility
ALL · 30 Years · 75 Years

Interventions & indications

Drugs
Omega-3 fish oil capsules (including DHA)

Sponsors

Université de MontréalLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Pierre J. Blanchet, MD, PhDPrincipal Investigator

Sites

2 total
Montreal, CanadaMontreal, Canada

Linked catalysts

1
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia — primary completion2010-02-01

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2010-02-01
Status
WITHDRAWN
relationships
The graph out of here
drug
Omega-3 fish oil capsules (including DHA)
drug
lead_sponsor
Université de Montréal
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Tardive Dyskinesia
indication
Schizophrenia
indication
Tardive Dyskinesia
indication
investigator
Pierre J. Blanchet, MD, PhD
person